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Yukmijihwang-tang (YMJ;Liu wei di huang tang (China),Rokumigan (Japan))hasbeen used inthe treatment ofdiseases including
renal disorder, cognitive vitality, and diabetes mellitus. However, there is very little information regarding the toxicity of YMJ to
give an assurance of safety for clinical treatment. To provide safety information for YMJ, we evaluated its acute and sub-chronic
toxicity in rats. The single-dose toxicity of YMJ was examined using Sprague-Dawley rats. Rats were treated with YMJ extract
orally at 0, 500, 1000, or 2000mg/kg body weight. After a single administration, clinical signs were observed every day for two
weeks, and body weights were measured ﬁve times, including an initial measurement on day 1 (the day of administration). In the
sub-chronic oral toxicity study, YMJ was administered to rats at 0, 500, 1000, or 2000mg/kg/day for 13 weeks. Mortalities, clinical
signs, body weight changes, food and water consumption, ophthalmologic ﬁndings, urinalysis, hematological and biochemical
parameters, gross ﬁndings, organ weights, and histological examination were monitored during the study period. We found no
mortality and no abnormalities in clinical signs, body weights, and necropsy ﬁndings for any of the animals in the acute and sub-
chronic studies followingoral administration in the rat at up to 2000mg/kg/day YMJ. YMJ may not have any single-dose toxicity;
the LD50 of YMJ was over 2000mg/kg, and it is safe for rats. The no-observed-adverse-eﬀect-level (NOAEL) was considered to be
2000mg/kg/day.
1.Introduction
Yukmijihwang-tang (YMJ; Liu wei di huang tang (China),
Rokumigan (Japan)) is a herbal formula that includes
six herbs: Rehmanniae Radix Preparata, Corni Fructus,
Dioscoreae Rhizoma, Moutan Cortex, Poria Sclerotium, and
Alismatis Rhizoma [1]. YMJ is one of the most commonly
used herbal formulas for body enrichment and is widely
used in traditional medicine in Korea, China, and Japan
for kidney disorders such as pollakiuria (urination at short
intervals) and edema [1, 2]. It was reported that YMJ was
the ﬁrst herbal formula to be used in traditional Korean
medicine [3]. In China, YMJ had the greatest market share in
traditional Chinese medicine, and the market size was about
US$633 million in 2009 [4]. Recently, reports have shown
thatYMJ is eﬀectivefor antiaging treatment, antioxidant and
free radical scavenging activities [5], memory enhancement
and preventionof neuronal degeneration[6, 7], and diabetes
mellitus treatment [8].
Medicinal herbs and herbal formulas are generally con-
sidered to be safer than conventional drugs. However, there
is no evidence for the quality, safety, and eﬃcacy of most
commonly used herbal formulas including YMJ. In addition,
very little information exists on the safety of YMJ for clinical
use.
To establish evidence-based toxicity data for YMJ, we
analyzed the literature, eﬃcacy, safety, and chemical con-
s t i t u e n t so fY M J .A sap a r to ft h es a f e t ye v a l u a t i o no fY M J ,
acute oral dose toxicity and a subchronic oral dose toxicity
studies were conducted to investigate the potential toxicity
afterasingle or13-weekrepeated oraldoseadministration of
YMJ in Sprague-Dawley rats. The present study was carried
out in compliance with good laboratory practice (GLP)
and the test guidelines of the Organization for Economic2 Evidence-Based Complementary and Alternative Medicine
Cooperation and Development(OECD) [9] and Korea Food
and Drug Administration (KFDA) [10, 11].
2.Materialsand Methods
2.1. Preparation of Yukmijihwang-Tang (YMJ) Extract. The
constituents of YMJ are listed in Table 1. Six constituents
of YMJ (20.64kg) were chopped, mixed, and extracted with
water at 100◦C for 120min in an Herb Extractor (COSMOS-
660, KyungSeo Machine Co., Inchon, Korea) and ﬁltered.
The aqueous extract was lyophilized using a freeze dryer
(PVTFD100R, Ilshin Lab. Ltd., Korea) and yielded 5.57kg of
brown powder (yield = 27.0%). Powdersof YMJ extract were
stored at 4◦C.
2.2. Analysis of Chemical Contents from YMJ by HPLC. The
chemicals used for the identiﬁcation and quantiﬁcation of
compounds within the YMJ extract include the following:
5-hydroxymethyl-2-furaldehyde (5-HMF, MW: 126.11) as a
component of Rehmanniae Radix Preparata; loganin (MW:
390.38) of Corni Fructus; paeoniﬂorin (MW: 480.46) and
paeonol (MW: 166.17) of Moutan Cortex.
YMJ extract (10mg) was dissolved in 1mL of 50%
methanol and ﬁltered througha 0.45-μms yri n geﬁ lt erbef or e
injection into the HPLC system. The HPLC system was
composed of an SCL-10A system controller, LC-6AD pump,
SPD-M10A diode array detector (Shimadzu, Kyoto, Japan),
and Phenomenex Luna C18 (5μm, 4.6mm × 250mm)
column. A gradient solvent system of methanol (A) and
water (B) was used as follows: 20% A/80% B (start), 50%
A/50% B (10–20min), and 100% A (40–60min) at a ﬂow
rate of 0.7mL/min. The chromatograms were obtained at a
wavelength of 240nm (Figure 1).
In order to make standard calibration curves, 5-HMF (1
to500μg/mL),loganin(0.1to100μg/mL),paeoniﬂorin(1to
100μg/mL), and paeonol (2.5 to 50μg/mL) were diluted in
50% methanol and injected into the HPLC to give individual
chromatograms. The calibration curves were plotted by
calculating the peak area ratio, which has a relatively smaller
errorthan thepeakheight ratio.The ﬁttingequationsof each
calibration curve were as follows: 5-HMF, y = 14905x −
70874 (r2 = 0.9998); loganin, y = 25362x − 3955.8( r2 =
0.9999); paeoniﬂorin, y = 15270x − 10013 (r2 = 0.9998);
paeonol, y = 19355x − 2039.1( r2 = 0.9996). The contents
of the chemicals in YMJ extract were measured as the
following:5-HMF3.70±0.11mg/g,loganin 1.77±0.05mg/g,
paeoniﬂorin 1.08±0.03mg/g, and paeonol 1.98±0.02mg/g.
2.3. Animals and Housing Conditions. For the acute and
subchronic toxicity studies, speciﬁc pathogen-free Sprague-
Dawley Crl:CD (SD) rats of both genders (ﬁve weeks
old) were obtained from OrientBio Co., Ltd. (Seoungnam,
Korea).Theanimals wereallowedtoacclimatizeforoneweek
before the initiation of experiments. Animals were housed
in a stainless wire cage (255mm W × 465mm L × 200mm
H) at ≤5 animals/cage for the quarantine period and at ≤2
animals/cage for the observation period. Pelleted food was
purchased from PMI Nutrition International (USA). The
pellet food was gamma-ray irradiated and given ad libitum.
Table 1: Composition of Yukmijihwang-tang(YMJ).
Herbs Scientiﬁc names Ratio
Rehmanniae Radix
Preparat
Rehmannia glutinosa Liboschitz
var. purpurea Makino 8
Dioscoreae Rhizoma Dioscorea batatas Decaisne 4
Corni Fructus Cornus oﬃcinalis Siebold et
Zuccarini 4
Hoelen Poria cocos Wolf 3
Moutan Cortex Paeonia suﬀruticosa Andrews 3
Alismatis Rhizoma Alisma orientale Juzepczuk 3
Tap water was given ad libitum, following UV irradiation
and ﬁltration. The water was analyzed at the Daejeon
Regional Institute of Health and Environment (Daejeon,
Korea). The animal room was maintained at a temperature
of 22 ± 3◦C, a relative humidity of 50 ± 10%, an air
ventilation frequency of 10∼20 times/hr, a light intensity of
150∼300 Lux, and a 12-hr light/dark cycle (08:00∼20:00).
The study was conducted according to the guidance of the
Institutional Animal Care and Use Committee at the Korea
Institute of Toxicology, KRICT (accredited by AAALAC
International 1998). The numbers of approval for the acute
and subchronic toxicity studies were G08109 and G08111,
respectively.
2.4. Group Assignment and Treatment. YMJ is widely used
as a traditional medicine and was not anticipated to cause
animal death following a single dose. The highest dose
of 2000mg/kg, with a common ratio of 2, was selected
for this study. YMJ extract was dissolved in distilled water
for injection (Choongwae Pharmaceutical, Ltd., Korea).
Distilled water wasgiven tothe animals in the vehiclecontrol
group. The animals were grouped into four groups with
ﬁve rats/sex/group at random, and YMJ was dissolved in
puriﬁed water and administered by oral gavage at doses of
0, 500, 1000, or 2000mg/kg body weight. The observations
of general condition, toxic symptoms, and mortality in rats
were monitored for 14 days after YMJ administration. The
grouping of animals in good health during the acclimation
period was carried out using the A-module of Path/Tox
System (Ver. 4.2.2, Xybion Medical Systems Corporation,
USA).
In the subchronic study, rats (10 rats/sex/group) were
randomly divided into four groups. A previous four-week
repeated dose study showed no abnormal changes even at
the highest dose, 2000mg/kg. Therefore, 2000mg/kg was
selected as the highest dose, with a common ratio of 2.
2.5. Observation and Examination
2.5.1.AcuteOral Toxicityin Rats. Mortality and clinicalsigns
were continually observed for 0, 1, 2, 3, 4, 5, and 6hr after
dosing on day 1 and at one time per day from day 2 to day
15.The animalswere weighed beforedosing(day1)andafter
dosing (days 2, 4, 8, and 15) using an electronic balance
(Sartorious Co., Germany). On day 15, all animals wereEvidence-Based Complementary and Alternative Medicine 3
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Figure 1: Chromatograms of standard components and Yukmijihwang-tang. The three major component herbs of Yukmijihwang-tang and
their main compounds were subjected to HPLC. The chromatograms were obtained at a wavelength of 240nm. 5-HMF ((a), retention time
(RT): 8.893min), loganin ((b), RT: 18.850min), paeoniﬂorin ((c), RT: 19.188min), paeonol ((d), RT: 35.604min), and Yukmijihwang-tang
extract (e).
euthanized by exsanguination from the abdominal aorta and
a b d o m i n a lv e n ac a v au n d e rC O 2 gas overdose and examined
for internal organ abnormalities.
2.5.2. Subchronic 13-Week Oral Toxicity in Rats. Mortality
and clinical signs were recorded once a day during the study
period using the Path/Tox Program (Ver. 4.2.2). Animals
were weighed on animal arrival, randomization, the ﬁrst day
of dosing, once a week thereafter, and at the termination of
the experiment. The amounts of food and water given and
their remnants on the next day were measured to calculate
the diﬀerence, which was regarded as daily consumption.
External eye examination was investigated during the pretest
period; both external and fundus examinations were com-
pleted using an indirect binocular ophthalmoscope (Vantage
Plus Digital, Keeler Ltd., UK).
During the last week of dosing, urinalysis was carried
out with urine collected over approximately 16hr from all
animals. Urinalysis measurements included urine volume,
speciﬁc gravity, pH, protein, ketone body, occult blood,
glucose, bilirubin, nitrite, urobilinogen, color, and sediment
(cast, epithelial cell, erythrocyte, and leucocyte). Urine
volume was measured using a mass cylinder, color with
macroscopic examination, and sediment using amicroscope.
The other parameters in the urinalysis were analyzed using
Multistix 10 SG strips (Bayer, USA) and a CliniTek-100
(Bayer, USA).
Animals were fasted over night prior to necropsy and
blood sampling. All living animals were anesthetized by
isoﬂurane inhalation, blood samples were taken, and then
the animals were sacriﬁced by exsanguination from the
aorta. Complete gross observation was performed on all
terminated animals. The blood samples were collected into
tubes containing EDTA-2K and analyzed for complete blood
cell counts. Complete blood cells were measured by an
ADVIA120 Hematology System (Bayer, USA). Prothrombin
time (PT) and activated partial thromboplastin time (APTT)
were analyzed with blood samples treated with 3.2% sodium
citrate using an ACL 9000 (Instrumentation Laboratory,
Italy).
Blood samples for serum biochemistry and hematology
were drawn from the posterior vena cava of all ani-
mals. Serum samples were prepared after blood centrifu-
gation and analyzed using a Toshiba 200FR NEO (Toshiba
Co., Japan). The following parameters were measured:
aspartate aminotransferase (AST), alanine aminotransferase
(ALT), alkaline phosphatase (ALP), blood urea nitrogen
(BUN), creatinine (CREA), glucose (GLU), total cholesterol
(TCHO), albumin/globulin ratio (A/G), total protein (TP),
albumin (ALB), creatine kinase (CK), triglyceride (TG),
total bilirubin (TBIL), phospholipid (PL), gamma glutamyl
transferase (GGT), calcium (Ca), inorganic phosphorus
(IP), chloride (Cl), sodium (Na), and potassium (K)
[12].4 Evidence-Based Complementary and Alternative Medicine
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Figure 2: Changes in body weight during a two-week acute toxicity study. (a) Male rats and (b) female rats.
Absolute organ weights were measured, and relative
organ weights (organ/body weight) were calculated for the
organs of all animals when sacriﬁced.
2.6. Statistical Analysis. Data collected during the study
were examined for variance homogeneity using the Bartlett’s
test. When the Bartlett’s test indicated no signiﬁcant devi-
ations from variance homogeneity, a one-way ANOVA was
performed at α = 0.05. When signiﬁcance was noted, a
multiple comparison test (Dunnett’s test) was conducted to
determine which groups were signiﬁcantly diﬀerent. In the
case that signiﬁcant deviations from variance homogeneity
were observed, a nonparametric comparison test (Kruskal-
Wallis test) was conducted. When a signiﬁcant diﬀerence
was observed in the Kruskal-Wallis test, the Dunn’s Rank
Sum test was conducted to perform pairwise comparisons
between pairs. Statistical analyses were performed using the
Path/Tox System (Ver. 4.2.2). The level of signiﬁcance used
was P<. 05or 0.01.Because treatment-related animal deaths
were not observed, the LD50 was not measured.
3.Results
3.1. Acute Oral Toxicity in Rats. There were no animal
deathsinanygroups.Therefore, theapproximatelethaldoses
of YMJ extract in male and female rats are higher than
2000mg/kg. Clinical signs observed included loss of fur in
1/5 males from day 11 until the end of the analysis and
2/5 females from day 4 until the end of the analysis in the
YMJ 2000mg/kg group. Normal body weight gains were
observed in males and females of all dose groups (Figure 2).
No signiﬁcant diﬀerences were observed between the vehicle
control and YMJ treatment groups. No abnormal gross
ﬁndings were observed in any animals.
3.2. Subchronic 13-Week Oral Toxicity in Rats. There were
no animal deaths during the study period. In males, clinical
signs observed during the study period included loss of
fur (1/10) and swollen pinna (1/10) in the vehicle control
group; loss of fur (1/10), swollen pinna (1/10), and scratch
wound (1/10) in the 500mg/kg group; loss of fur (4/10) and
scratch wound (2/10) in the 1000mg/kg group; loss of fur
(2/10) and scratch wound (2/10) in the 2000mg/kg group.
In the females, clinical signs included loss of fur (1/10)in the
vehicle control group; loss of fur (4/10) and scratch wound
(1/10) in the 500mg/kg group; loss of fur (2/10) in the 1000
mg/kg group; loss of fur (3/10) in the 2000mg/kg group.
Notreatment-related bodyweightchangeswereobserved
during the study period (Figure 3). An increase (16%) in
food consumption measured at day 86 was observed in the
500 and 1000mg/kg groups compared to the vehicle control
group (Figure 4). The overall water consumption of animals
receiving the YMJ extract was generally similar to that of the
vehicle control (data not shown).
Inophthalmologicalexamination, noabnormalitieswere
noted in any animals. No treatment-related changes were
observed in urinalysis during the study period. Hematolog-
ical examination performed at necropsy showed an increase
in NEU% (50%) and a decrease in LYM% (9%) in the male
1000mg/kg group (Table 2). Serum biochemical examina-
tion performed at female necropsy showed a decrease in
AST (20%) in the 1000mg/kg group and a decrease in TBIL
(14%) in the 2000mg/kg group (Table 3).
Gross ﬁndings at male necropsy included swollen pinna
(1/10) and irregular surface of lung (1/10) in the vehicle
control group, swollen pinna (1/10) in the 500mg/kg group,
small testes and epididymis (1/10) in the 1000mg/kg group,
and a scratched wound on face (1/10) in the 2000mg/kg
group. In females, gross ﬁndings included focus/foci inEvidence-Based Complementary and Alternative Medicine 5
Table 2: Hematologicalparameters of male and female rats on subchronic toxicity study.
(a) Male (b) Female
Parameter Vehicle
control
YMJ-
500mg
YMJ-
1000mg
YMJ-
2000mg
Vehicle
control
YMJ-
500mg
YMJ-
1000mg
YMJ-
2000mg
WBC (×103/μL) 12.10 ±1.04 10.72 ±1.06 10.49 ±0.48 10.83 ±0.58 8.74 ± 0.71 8.54 ±0.72 7.56 ± 0.71 9.33 ±0.91
Reticulocytes (%) 2.1 ±0.12 .3 ±0.22 .0 ±0.12 .3 ±0.11 .9 ± 0.11 .7 ±0.11 .9 ± 0.12 .3 ±0.1
Neutrophils (%) 14.46 ±1.39 18.57 ±1.82 21.65 ±
1.76
∗∗ 18.37 ±1.10 13.07 ± 2.25 13.27 ±1.57 15.91 ± 0.74 14.98 ±2.31
Lymphocytes (%) 77.8 ±1.67 4 .3 ±1.97 1 .0 ±1.7
∗∗ 75.1 ±1.28 0 .4 ± 2.27 9 .2 ±1.77 6 .9 ± 0.87 9 .1 ±2.2
Eosinophils (%) 1.1 ±0.11 .1 ±0.21 .2 ±0.11 .1 ±0.21 .2 ± 0.21 .2 ±0.21 .2 ± 0.11 .1 ±0.1
Monocytes (%) 4.7 ±0.44 .5 ±0.34 .5 ±0.33 .6 ±0.33 .6 ± 0.34 .6 ±0.74 .0 ± 0.33 .3 ±0.2
Basophils (%) 0.7 ±0.10 .7 ±0.10 .6 ±0.10 .7 ±0.10 .7 ± 0.10 .7 ±0.10 .9 ± 0.10 .7 ±0.1
LUC (%) 1.3 ±0.10 .9 ±0.11 .0 ±0.11 .1 ±0.21 .0 ± 0.10 .9 ±0.11 .1 ± 0.20 .9 ±0.1
RBC (×106/μL) 8.63 ±0.16 8.65 ±0.13 8.70 ±0.14 8.66 ±0.11 8.19 ± 0.09 8.20 ±0.13 8.38 ± 0.11 7.92 ±0.09
Hemoglobin
(g/dL) 15.7 ±0.41 6 .1 ±0.11 6 .1 ±0.31 6 .4 ±0.11 6 .1 ± 0.31 6 .0 ±0.31 6 .3 ± 0.21 5 .9 ±0.2
Hmatocrit (%) 44.6 ±1.04 5 .4 ±0.54 5 .4 ±0.74 6 .0 ±0.54 4 .9 ± 0.64 4 .1 ±0.74 5 .3 ± 0.44 3 .8 ±0.5
MCV (fL) 51.7 ±0.85 2 .5 ±0.95 2 .2 ±0.75 3 .1 ±0.55 4 .9 ± 0.55 3 .8 ±0.55 4 .1 ± 0.45 5 .4 ±0.6
MCH (pg) 18.2 ±0.31 8 .7 ±0.31 8 .5 ±0.31 9 .0 ±0.21 9 .7 ± 0.21 9 .5 ±0.21 9 .5 ± 0.22 0 .1 ±0.2
MCHC (g/dL) 35.2 ±0.13 5 .5 ±0.23 5 .4 ±0.23 5 .8 ±0.23 5 .9 ± 0.23 6 .3 ±0.23 6 .0 ± 0.33 6 .3 ±0.3
Platelet
(×103/μL) 1048 ±24 1034 ±36 1053 ± 36 1065 ±49 1089 ± 48 1080 ±48 1098 ±20 1051 ±38
PT (sec) 16.1 ±0.41 5 .5 ±0.31 6 .0 ±0.41 6 .8 ±0.61 4 .5 ± 0.21 4 .3 ±0.21 4 .2 ± 0.31 4 .1 ±0.1
APTT (sec) 18.6 ±0.41 8 .8 ±0.61 8 .2 ±0.41 8 .8 ±0.31 5 .0 ± 0.21 4 .8 ±0.51 5 .3 ± 0.41 5 .1 ±0.4
Values are mean ± SEM for 10 rats in each group. ∗∗,s i g n i ﬁ c a n td i ﬀerences from the vehicle control (0) group (P<. 0 1 ) .W B C :w h i t eb l o o dc e l l s ;L U C :
large unstained cells; RBC: red blood cells; MCV: mean corpuscular volume; MCH: mean corpuscular hemoglobin; MCHC: mean corpuscular hemoglobin
concentration; PT: prothrombin time; APTT: activated partial prothrombin time.
0
100
200
300
400
500
600
Male
B
o
d
y
w
e
i
g
h
t
(
g
)
024681 0 1 2 1 4
Control
YMJ-500mg/kg
Weeks on study
YMJ-1000mg/kg
YMJ-2000mg/kg
(a)
0
100
200
300
Female
B
o
d
y
w
e
i
g
h
t
(
g
)
02468 1 0 1 2 1 4
Control
YMJ-500mg/kg
Weeks on study
YMJ-1000mg/kg
YMJ-2000mg/kg
(b)
Figure 3: Increase in body weight during the 13-week subchronic toxicity study. (a) Male rats and (b) female rats.
the adrenal glands (1/10) in the vehicle control group and
nodule in the kidneys (1/10), adhesion in the diaphragm
(1/10), hemorrhage in the thoracic cavity (1/10), and
discoloration of the thymus (1/10) in the 2000mg/kg group.
Organ weights measured at female necropsy showed a
decrease (33%) in the absolute weight of the uterus/cervix
in the 500mg/kg group and an increase (9%) in the relative
weight of the liver in the 2000mg/kg group (Table 4).
In histopathological examination, lesions such as inﬂam-
matory cell foci in the liver and kidneys, mineralization
in the kidneys, and cardiomyopathy in the heart in males
and females in the 2000mg/kg groups were also detected in6 Evidence-Based Complementary and Alternative Medicine
Table 3: Serum biochemical parameters of male and female rats on subchronic toxicity study.
(a) Males (b) Females
Parameter Vehicle
control
YMJ-
500mg
YMJ-
1000mg
YMJ-
2000mg
Vehicle
control
YMJ-
500mg
YMJ-
1000mg
YMJ-
2000mg
Glucose (mg/dL) 120.1 ±6.9 118.8 ±4.6 117.2 ± 5.5 110.6 ±4.4 113.8 ±10.4 107.2 ± 6.5 117.4 ±5.3 107.6 ±10.0
BUN (mg/dL) 13.3 ±0.81 3 .8 ±0.51 3 .8 ± 0.51 3 .9 ±0.71 6 .8 ±0.71 5 .7 ± 0.81 6 .3 ±0.8 16.3 ±0.7
Creatinine (mg/dL) 0.51 ±0.02 0.54 ±0.01 0.51 ± 0.01 0.53 ±0.01 0.63 ±0.02 0.59 ± 0.00 0.60 ±0.02 0.61 ±0.03
Total protein (g/dL) 6.85 ±0.14 6.75 ±0.09 6.79 ± 0.13 6.80 ±0.12 7.16 ±0.17 7.23 ± 0.11 7.10 ±0.19 7.25 ±0.16
Albumin (g/dL) 4.25 ±0.06 4.23 ±0.04 4.26 ± 0.05 4.27 ±0.05 4.67 ±0.10 4.71 ± 0.07 4.59 ±0.11 4.70 ±0.09
A/G (ratio) 1.64 ±0.04 1.69 ±0.04 1.69 ± 0.05 1.69 ±0.03 1.90 ±0.05 1.87 ± 0.04 1.83 ±0.03 1.85 ±0.04
TCHO (mg/dL) 66.2 ±8.26 7 .8 ±4.26 6 .6 ± 3.76 4 .9 ±5.87 2 .0 ±4.27 3 .7 ± 4.07 1 .2 ±4.6 73.2 ±5.6
Triglyceride (mg/dL) 53.1 ±8.05 7 .3 ±9.75 8 .6 ± 11.74 9 .1 ±6.94 3 .3 ±5.14 2 .5 ± 4.23 7 .3 ±4.33 6 .1 ±3.3
Phospholipid (mg/dL) 104 ±9 104 ±6 104 ± 5 100 ±8 139 ±7 138 ± 7 137 ±8 134 ±10
AST (IU/dL) 107.8 ±4.1 103.6 ±6.0 101.6 ± 7.1 103.1 ±6.1 133.3 ±7.2 116.3 ± 5.9 106.6 ±
4.1
∗∗ 113.7 ±7.8
ALT (IU/dL) 33.8 ±1.53 0 .4 ±0.93 2 .5 ± 2.53 1 .0 ±0.93 6 .3 ±2.73 1 .5 ± 1.33 0 .6 ±3.2 28.6 ±1.8
TBIL (mg/dL) 0.140 ±
0.005
0.149 ±
0.007
0.132 ±
0.004
0.134 ±
0.003
0.158 ±
0.006
0.147 ±
0.007
0.145 ±
0.005
0.136 ±
0.004
∗
ALP (IU/dL) 196.1 ±6.8 199.1 ±15.3 216.9 ± 13.9 222.6 ±18.0 103.6 ±4.5 105.4 ± 10.1 124.9 ±14.6 86.0 ±5.7
CK (IU/dL) 472 ±46 449 ±50 459 ± 75 401 ±45 553 ±56 517 ± 40 418 ±34 552 ±59
Ca (mg/dL) 10.90 ±0.15 10.85 ±0.08 10.80 ± 0.17 10.86 ±0.13 11.31 ±0.22 11.13 ± 0.19 11.05 ±0.25 11.21 ±0.18
IP (mg/dL) 10.05 ±0.26 9.27 ±0.27 9.23 ± 0.31 9.55 ±0.31 8.02 ±0.49 8.16 ± 0.37 7.99 ±0.38 8.25 ±0.48
Na (mg/dL) 144 ±0 144 ±1 146 ± 1 145 ±1 144 ±0 145 ± 0 145 ±1 144 ±1
K( m g / d L ) 8 .84 ±0.42 8.12 ±0.52 8.00 ± 0.56 9.15 ±0.61 7.72 ±0.19 7.03 ± 0.20 7.32 ±0.13 7.16 ±0.31
Cl (mg/dL) 101 ±1 101 ±0 102 ± 1 102 ±0 103 ±1 103 ± 1 103 ±0 102 ±1
GGT (mg/dL) 0.00 ±0.00 0.00 ±0.00 0.00 ± 0.00 0.00 ±0.00 0.00 ±0.00 0.25 ± 0.26 0.01 ±0.01 0.02 ±0.02
Values are mean ± SEM for 10 rats in each group. ∗:s i g n i ﬁ c a n td i ﬀerences from the vehicle control (0) group (P<. 05). ∗∗:s i g n i ﬁ c a n td i ﬀerences from
the vehicle control (0) group (P<. 01). BUN: blood urea nitrogen; A/G: albumin/globulin; TCHO: total cholesterol, AST: aspartate aminotransferase; ALT:
alanine aminotransferase;TBIL: total bilirubin; CK: creatine kinase; ALP: alkaline phosphatase; IP: inorganic phosphorus; GGT: gammaglutamyltransferase.
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Figure 4: Food consumption of rats administrated Yukmijihwang-tang orally for 13 weeks. (a) Male rats and (b) female rats.Evidence-Based Complementary and Alternative Medicine 7
Table 4: Absolute organ weights (g) of male and female rats on subchronic toxicity study.
(a) Males (b) Females
Parameter Vehicle
control
YMJ-
500mg
YMJ-
1000mg
YMJ-
2000mg
Vehicle
control
YMJ-
500mg
YMJ-
1000mg
YMJ-
2000mg
Brain 2.08 ±0.03 2.15 ±0.03 2.10 ± 0.04 2.07 ±0.03 1.95 ±0.03 1.90 ± 0.02 1.88 ±0.02 1.91 ±0.02
Pituitary 0.013 ±
0.001
0.012 ±
0.001
0.012 ±
0.001
0.013 ±
0.001
0.017 ±
0.001
0.014 ±
0.001
0.015 ±
0.001
0.016 ±
0.001
Liver 13.85 ±0.73 14.45 ±0.58 14.08 ± 0.72 13.85 ±0.79 7.35 ±0.23 6.95 ± 0.30 6.99 ±0.32 7.62 ±0.21
Spleen 0.810 ±
0.069
0.842 ±
0.045
0.763 ±
0.038
0.765 ±
0.043
0.520 ±
0.018
0.466 ±
0.031
0.480 ±
0.027
0.500 ±
0.027
Adrenal gland 0.064 ±
0.002
0.062 ±
0.004
0.059 ±
0.002
0.063 ±
0.003
0.072 ±
0.004
0.065 ±
0.002
0.065 ±
0.003
0.068 ±
0.002
Kidneys 3.51 ±0.14 3.41 ±0.13 3.42 ± 0.11 3.42 ±0.15 1.90 ±0.05 1.80 ± 0.06 1.89 ±0.09 1.89 ±0.26
Heart 1.58 ±0.05 1.56 ±0.06 1.55 ± 0.04 1.55 ±0.07 0.98 ±0.02 0.93 ± 0.04 0.89 ±0.03 0.95 ±0.03
Thymus 0.381 ±
0.027
0.450 ±
0.027
0.418 ±
0.040
0.404 ±
0.023
0.348 ±
0.026
0.319 ±
0.032
0.314 ±
0.027
0.324 ±
0.024
Salivary glands 0.710 ±
0.020
0.773 ±
0.023
0.701 ±
0.021
0.732 ±
0.037
0.426 ±
0.011
0.429 ±
0.018
0.436 ±
0.023
0.425 ±
0.015
Lung 1.57 ±0.04 1.67 ±0.05 1.60 ± 0.05 1.59 ±0.09 1.20 ±0.02 1.19 ± 0.04 1.14 ±0.03 1.23 ±0.04
Thyroid/Parathyriod 0.025 ±
0.002
0.024 ±
0.002
0.025 ±
0.002
0.023 ±
0.002
0.015 ±
0.002
0.014 ±
0.001
0.015 ±
0.001
0.014 ±
0.001
Epididymides 1.52 ±0.03 1.45 ±0.04 1.48 ± 0.06 1.50 ±0.0 4 ————
Seminal vesicle 1.80 ±0.10 1.83 ±0.07 1.75 ± 0.07 1.97 ±0.0 9 ————
Prostate 0.726 ±
0.039
0.692 ±
0.036 0.705±0048 0.745 ±
0.038 ————
Testes 3.49 ±0.11 3.23 ±0.07 3.26 ± 0.18 3.34 ±0.0 6 ————
O v a r i e s ———— 0.088 ±
0.004
0.078 ±
0.004
0.079 ±
0.004
0.084 ±
0.028
Uterus/Cervix — — — — 0.830 ±
0.078
0.556 ±
0.049
∗
0.847 ±
0.083
0.638 ±
0.097
Values are mean ± SEM for 10 rats in each group. ∗:s i g n i ﬁ c a n td i ﬀerences from the vehicle control (0) group (P<. 05). ∗∗:s i g n i ﬁ c a n td i ﬀerences from the
vehicle control (0) group (P<. 01).
the vehicle control group with similar incidence rates. The
acanthosis and chondropathy in the ear, chronic dermatitis
of the skin, M-nephroblastoma in the kidney, pigmented
macrophages in the thymus, tubular atrophy in the testes,
and aspermia in the epididymides were not dose dependent
and occurred at low incidence rates. There were other lesions
that were considered to be spontaneous or nontreatment
related.
4.Discussion
Globally, the increasing use of complementary and alterna-
tivemedicine(CAM)suchasherbalremediesmaybeduetoa
variety of factors, including the limits of current therapy and
adverse eﬀectsof conventional drugs [13]. Traditional herbal
medicine is the most important part of CAM and has been
utilized for treating diseases and promoting the health of
humans for thousands of years; in addition, it has become a
popular alternative choice conventional medicine. Although
there are many traditional herbal medicine interventions
available, and some have been veriﬁed by clinical trials, their
eﬃcacy and safety are still questioned by consumers [14].
YMJ is one of the most popular herbal formulas in Asian
countries; however, evidence-based information is limited.
Many studies have reported pharmacological eﬃcacies and
beneﬁts of YMJ, but there is no information on its risk and
safety such as its acute and subchronic toxicity.
To evaluate the acute toxicity, YMJ extract was orally
given at doses 0, 500, 1000, or 2000mg/kg to male and
female Crl:CD (SD) rats. Mortalities, clinical signs, body
weight changes, and gross ﬁndings were monitored for 14
days (days 1∼15). The loss of fur observed in some animals
at the highest dose group (2000mg/kg) has been observed in
control SD rats also and considered to be due to individual
variation.
No treatment-related toxicity was observed in the study
carried out to evaluate the subchronic 13-week repeated
oral dose toxicity of YMJ extract. Some changes noted in
the clinical observation, food consumption, hematology,
serum biochemistry, gross ﬁndings, and organ weights were
considered to be not treatment-related but incidental and
withinnormalranges.Histopathologicalﬁndings,suchasthe
inﬂammatory cell foci in the liver and kidneys, mineraliza-
tion in the kidneys, and cardiomyopathy in the heart were8 Evidence-Based Complementary and Alternative Medicine
also observed in the vehicle control group at similar levels
and incidence rates, indicating no toxicological signiﬁcance.
Lesions such as acanthosis and chondropathy in the ear,
chronic dermatitis of the skin, tubular atrophy in the testes,
and aspermia in the epididymides were considered to be
associated with gross ﬁndings but appear to be incidental
because of a lack of dose dependency and low incidence
rates. There were other lesions that were considered to be
spontaneous or not related to the treatments.
Consequently, no acute toxicity was found in rats treated
with YMJ extract, and approximate lethal doses for males
and females were higher than 2000mg/kg. The 13-week
repeated oral administration of YMJ in SD rats showed no
toxicity and a no-observed-adverse-eﬀect-level (NOAEL) of
2000mg/kg/day.
In humans, the reported single dose of YMJ is about
46.875g dried herb [1], which is equivalent to 12.656g of
the extract (yield of extract = 27.0% of the raw material).
Considering the average body weight of an adult as 60kg,
the dose for a 60kg human is 211mg of YMJ extract/kg. To
convert the human dose to rat dose equivalent, the amount
would be 1,329mg/kg (211mg/kg × 6.3) according to van
Miert [15]. The dose equivalent per kg for rat (6.3) was
derived by dividing the Km factor, body surface area (m2)
to body weight (kg) ratio, for humans with the Km factor for
rat [15]. The amount of YMJ extract, 1,329mg, is a value less
than the NOAEL (2000mg/kg in rats).
In conclusion, the present studies demonstrate that at
doses consumed in traditional medicine, the aqueousextract
of YMJ may be relatively safe because it did not cause any
lethality or changes in the general behavior in rats in both
the acute and subchronic toxicity studies.
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